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Abstract
The aim of this review is to summarize the contribution of platelets and leukocytes and their 
interactions  in  inflammation  and  blood  coagulation  and  its  possible  relevance  in  the 
pathogenesis  of  thrombosis.  There  is  s
infection/inflammation  and  thrombosis.  This  is  likely  a  bidirectional  relationship.  The 
presence of a thrombus may serve as a nidus of infection. Vascular injury indeed promotes 
platelet  and  leukocyte  activation  and  t
components facilitate adherence of bacteria to the vessel wall. Alternatively, an infection and 
the  associated  inflammation  can  trigger  platelet  and  leukocyte  activation  and  thrombus 
formation.  In  either  case  platelets  and  leukocytes  co
vascular injury, at sites of inflammation and/or at sites of thrombosis.
injury, the subendothelial tissue, a thrombogenic surface, becomes available for interaction 
with these blood cells. Tissue factor, found not only in media and adventitia of the vascular 
wall,  but  also  on  activated  platelets  and  leukocytes,  triggers  blood  coagulation.  Vascular
blood cell interactions, mediated by the release of preformed components of t
is  modulated  by  both  cell  adhesion  and  production  of  soluble  stimulatory  or  inhibitory 
molecules that alter cell function: adhesion molecules regulate cell
the  modulation  of  biochemical  pathways  relevant  to  infla
processes.
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Introduction: At sites of inflammation, infection or 
vascular  injury,  local  pro-inflammatory  or 
pathogen-derived  stimuli  render  the  luminal 
vascular endothelial surface attractive for platelets 
and  leukocytes.  This  cell  response  consists  of  a 
well-defined  and  regulated  multi-step  cascade 
involving consecutive steps of adhesive interactions 
between  blood cells and the endothelium. Platelets 
arrive early at sites of inflammation contributing to 
both  coagulation  and  to  the  immune  response,  in 
part  by  facilitating  leukocyte-endothelial 
interactions. Platelets have thereby been implicated 
in several inflammatory disorders. During the initial 
contact  with  the  activated  endothelium  and 
platelets, leukocytes roll along the endothelium via 
a loose bond which is mediated by selectins. This 
preliminary  step  results  in  the  activation  of 
leukocyte integrins and the firm leukocyte arrest on 
the  endothelium.  After  their  firm  adhesion, 
leukocytes  may  pass  the  endothelial  barrier.  In 
addition to the injured vessel wall, circulating blood 
cells, reaching the sites of inflammation, contribute 
to blood coagulation by facilitating availability of 
vascular or blood-borne tissue factor. 
It  is  currently  accepted that  thrombosis  – the 
most  common  cause  of  ischemic  cardiovascular 
disease, such as myocardial infarction and stroke –
is  the  late  complication  of  atherosclerosis,  a 
progressive inflammatory disease characterized by 
lipid  infiltration  in  the  wall  of  large  arteries 
(atherosclerotic  plaques).  Platelet  and  leukocyte 
recruitment on endothelial cells constitutes an early 
mechanism  of  vascular  inflammatory damage  and 
consequent plaque formation and vessel occlusion.
1
Plaque rupture and thrombosis are the major causes 
of myocardial infarction and sudden cardiac death; 
the  mechanisms  of  lesion  vulnerability,  based  on 
the  cellular  and  matrix  contribution  to  tissue 
proteolysis, are responsible for thinning and rupture 
of the fibrous cap.
2 During inflammation, signalling 
cascades  result  in  activation  of  endothelial  cells, 
platelets  and  leukocytes.  The complex  interaction 
between these vascular cells is influenced by both 
cell adhesion and production of soluble stimulatory 
or inhibitory molecules that alter cell function: an 
array of cell-cell adhesion molecules regulates this 
close relationship which favours the modulation of 
the biochemical pathways of these cells, while the 
interaction among soluble molecules triggers blood 
coagulation,  a  fibrin  mesh  is  formed,  and  the 
resulting clot limits or stops the loss of blood. The 
net effect of this cellular cross-talk on inflammation 
depends on the balance between inputs and can lead 
to  resolution  and  repair  or  perpetuation  of 
inflammation, atherosclerosis and thrombosis.
3-6 In 
this  review,  we  will  focus on the  mechanisms of 
vascular  and  blood  cell  interactions,  that  are 
relevant for thrombosis and inflammation and their 
physio-pathological  relevance,  based  on  both 
experimental and epidemiological data. 
Cell-Cell Interactions In Thrombosis
Adhesion  of  platelets  and  leukocytes  to 
endothelial cells: The first description of rolling of 
blood cells along the endothelial surface of venules 
was  reported  more  than  160  years  ago  when 
leukocytes were  shown to  adhere to  blood  vessel 
walls,  an  interaction that  increased  in 
inflammation.
7 Giulio  Bizzozero  in  1882  first 
described  platelets  as  a  new  blood  corpuscle, 
playing  a  relevant  role  in  thrombosis  and 
haemostasis, and observed that “Every time when a 
vascular wall  is damaged… arrest  of  white blood 
corpuscles represents a secondary phenomenon and 
may, perhaps, be caused by increased stickiness of 
blood platelets whereby the latter react with white 
blood  corpuscles  which  have  been  brought  in 
contact with the former by blood circulation”.
8
Many  decades  later,  the  modern  version  of 
intravital microscopy allowed the first quantitative 
observations of leukocyte rolling in the cheek pouch 
of hamsters and in mouse mesentery.
9
Platelet  adhesion  to  and  leukocyte  rolling  on 
endothelium  are  the  initial  stage  of  a  multistep 
process leading to extravasation of white blood cells 
to  sites  of  inflammation  or  infection,  to  platelet-
leukocyte  interaction  and  aggregation  on  a 
thrombogenic  surface  and  finally  to  vascular 
occlusion. Platelets may interact with endothelium 
even in the absence of any apparent morphological 
damage.  They  may  stick  indeed  to  an  apparently 
intact  endothelium  inflamed  by  different  stimuli, 
such as infection, mechanic alteration or ischemia 
and reperfusion or to endothelium located at lesion-
prone sites, such as the carotid artery bifurcation. 
The recruitment of platelets and leukocytes at sites 
of vascular injury is a very rapid response and is 
mediated by the release of preformed components 
of the endothelium, including Weibel-Palade bodies 
and  their  major  constituents,  the  von  Willebrand 
factor’s largest multimers and P-selectin; these are 
the most active promoters of platelet and leukocyte 
adhesion.  P-selectin  mediates  both  leukocyte  and 
platelet adhesion and during secretion fuses with the 
endothelial  plasma  membrane.  The  process  of 
leukocyte rolling is initiated by P-selectin secretion 
and  is  concluded  by  leukocyte  adhesion  and 
transmigration to inflamed tissue.
3-5,10,11Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
Figure 1. Schematic sequence of interactions between endothelial cells, platelets and leukocytes. Reprinted from de Gaetano et al,
11 
with permission of the Publisher.
The schematic sequence of interactions between 
endothelial cells, platelets and leukocytes flowing in 
blood, that lead to vascular damage and thrombus 
formation, is depicted in Figure 1.
Platelets activated at the site of vascular damage 
play a pivotal role in polymorphonuclear leukocyte 
accumulation  in  a  growing  thrombus  and  may 
replace  endothelial  cells  in  the  recruitment  and 
migration  of  leukocytes  through  damaged  vessel 
wall. Platelets, on the other hand, may participate in 
inflammatory  responses,  for  instance  in  the 
autoimmune  disease  rheumatoid  arthritis  by 
providing  proinflammatory  microparticles,  formed 
upon  collagen-induced  platelet  activation,
12 or  in 
cutaneous arthus reaction by controlling cutaneous 
inflammation  via  P-selectin-PSGL-1.
13 Platelet  α-
granules  contain  and  release  P-selectin  on  their 
surface  upon  activation;  since  the  density  of  P-
selectin on activated platelets is much higher than 
that on endothelium, leukocytes are easily recruited 
onto  the  activated  platelets  either  adherent  to  the 
endothelium or in suspension. They roll on platelets 
and after activation transmigrate, or accumulate in a 
platelet  thrombus.  It  should  be  mentioned  that 
platelet-monocyte  complexes  show  increased 
transmigration  compared  to platelet-free 
monocytes.
14,15 Leukocytes can contribute in turn to 
further  platelet  activation  and  to  increased  fibrin 
deposition.
11,16,17
Early studies revealed that platelets, in in vitro
co-culture  experiments,  provide  a  cholesterol-
donating  activity  to  peripheral  blood  monocytes-
derived  macrophages,  enhancing  both  the  rate  of 
cholesteryl  ester  formation  and  accumulation.
18
Platelet factor 4 (PF4), which is stored in platelets 
and released upon activation, induces monocytes to 
macrophages differentiation and favours foam cell 
development  through  increased  oxLDL  uptake by 
macrophages.
19 In addition, as shown by Daub et 
al,
20 platelets  can  induce  the  transformation  of 
CD34
+ progenitor cells into mature foam cells. In 
this respect, the close association between platelets 
and  macrophages  in  the  early  fatty  streak  lesion 
might  favour  the  formation  of  foam  cells  and, 
consequently, the progression of the lesion. These 
events may on one hand, favour the maintenance of 
vascular and tissue  integrity, on the other, play a 
pathogenetic  role  in inflammatory  and thrombotic 
disease. A number of data provide indeed biological 
plausibility  to  the  epidemiological  evidence  of  a 
significant association between leukocyte count and 
the incidence of coronary heart disease.
21-23
Sequence  of  molecular  events  following  P-
selectin  expression:  P-selectin  is  a  type-1 
membrane  glycoprotein  with  a  C-type  lectin 
domain,  stored  in  the  Weibel-Palade  bodies  of 
endothelial cells and in the α-granules of platelets.
24
The  secretion  of  Weibel-Palade  bodies  initiates  a Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
multistep process of leukocyte recruitment. In the 
systemic microvasculature, leukocytes are captured 
and begin to roll on P-selectin, expressed in acute 
rapid  injury,  and  on  E-selectin  expressed in 
inflammatory  conditions;  in  specialized 
endothelium,  such  as  lymph  nodes,  initial 
interaction  can  be  mediated  by  other  molecules, 
such as L-selectin. Selectins recognize a specialized 
fucosylated  sialoglycoconjugate,  such  as  the 
tetrasaccharide  sialyl  Lewis  X  that  decorates
selected  surface  glycoproteins.  The  most  studied 
ligand is P-selectin glycoprotein ligand-1 (PSGL-1), 
enriched  at  the  very  tip  of  leukocyte  microvilli, 
which plays  a major role in the initial  capture of 
leukocytes  to  the  endothelium. PSGL-1  and  the 
recently  described  E-selectin  ligand  contribute  to 
leukocyte  capture  on  endothelium,  while  CD44, 
found on leukocytes, controls rolling velocity and 
signal transduction. Slow rolling allows leukocytes 
to interact with chemokines produced by inflamed 
tissues, further contributing to leukocyte activation. 
Recruitment  specificity  may  be  provided  or 
enhanced to certain tissues by unique combination 
of  adhesion  receptors  and  chemokines.  As 
inflammation progresses, leukocyte rolling velocity 
decreases,  allowing  the  integration  of  activation 
signals from selectin ligands and heterotrimeric G-
protein-coupled  receptors.  Downstream  signal 
effectors  include  phosphatidylinositol  3-kinase 
(PI3K),  phospholipase  C,  tyrosine  kinases  from 
different families and small GTPases. These signals 
lead to the polarization of slowly rolling leukocytes 
and clustering of L-selectin and PSGL-1 to a major 
pole  that  allows  further  leukocyte  recruitment 
through secondary leukocyte-leukocyte interactions. 
P-selectin- and E-selectin-induced signals may also 
collaborate  with  chemokine  receptor  signalling  to 
activate integrins.
5
P-selectin- β2-integrin  cross-talk:  Integrins  are 
heterodimers formed by an α and β chain, that are 
normally  found  in  a  closed  low-affinity 
conformation  on  leukocytes.  Different 
conformations,  with  matched  affinity  states,  exist 
and  leukocyte  activation  results  in  increased 
integrin  affinity  and  avidity  (strength  of 
adhesiveness),  leading  to  firm  adhesion  on 
endothelial  intercellular  adhesion  molecule-1 
(ICAM-1)  and  vascular  cell  adhesion  molecule-1 
(VCAM-1).  Adherent  leukocytes  continue  to 
migrate  along  the  vascular  wall,  until  they 
transmigrate either through the cell junctions among 
different  adhesive  molecules,  or  through  the 
endothelial cell itself. 
Leukocytes are recruited on activated platelets 
with  molecular  mechanisms  similar  to  those  just 
described,  occurring  at  the  site  of vascular 
inflammation.
11
A variety of agonists can activate platelets and 
induce α-granule release and P-selectin expression 
on  platelet  surface:  products  of  vascular  damage 
(multimeric von Willebrand factor), subendothelial 
collagen, traces of thrombin, the end product of the 
coagulation cascade, ADP, released by red cells or 
by  activated  platelets,  platelet  activating  factor 
(PAF)  or  active  products  of  the  arachidonic  acid 
metabolism,  such  as  thromboxane  A2,  proteases 
released  by  activated  polymorphonuclear 
leukocytes,  such  as  cathepsin  G,  chemokines  or 
other  inflammatory  mediators.  Activated  platelets 
within the circulation bind to leukocytes, forming 
platelet-leukocyte  conjugates,  through  P-selectin 
interaction  with  PSGL-1,  by  a  rapidly  reversible 
tethering.  PSGL-1  engagement  induces  in 
leukocytes  a  signal  that  facilitates  β2-integrin 
adhesiveness, through involvement of activation of 
tyrosine  kinases,  mainly  of  the  Src  family,  and 
allows the remodelling of cytoskeleton-β2-integrin 
linkages and clustering, that finally strengthen cell-
cell  adhesion.  At  variance  with  the  adhesive 
molecules involved in rolling, which do not require 
activation,  β2-integrins  require  functional  up-
regulation  to  become  competent  to  bind  their 
counter-receptor.  The  leukocyte  β2-integrin, 
CD11b-CD18  (or  Mac-1),  by binding  to  platelet 
counter-receptors, such as fibrinogen, ICAM-2 and 
GpIbα, can stabilize the interaction with platelets, 
but  can  also  interact  with  ligands  on  other  cells, 
such  as  endothelial  cells  or  different  classes  of 
leukocytes, allowing multicellular interactions.
10
Other adhesive systems: In the past decade other 
two  adhesive  proteins,  both  relevant  for  cell-cell 
interactions,  have  been  described  on  platelets, 
namely  CD40  and  CD40  ligand  (CD40L  or 
CD154).
25The  latter  is  translocated to  the  platelet 
surface after stimulation and may interact with its 
counter-receptor CD40, present on platelets and on 
endothelial  and  monocytes/macrophages,  thus 
facilitating  platelet  interaction  with  other  blood 
cells.  The  interaction  CD40L-CD40,  besides 
promoting cell-cell adhesion, induces up-regulation 
of  several  functions  in  monocytes,  such  as 
chemokine and cytokine secretion, expression of the 
pro-coagulant tissue factor (TF), up-regulation and 
activation of adhesive receptors and proteases and 
differentiation  of  monocytes  into  macrophages.
26
Different  mediators and pathways are involved in 
CD40  signal  transduction:  among  the  earliest Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
detectable events after CD40 activation have to be 
mentioned the activation of protein tyrosine kinases, 
phosphoinositide-3 kinase  and phospholipase Cγ2. 
After early biochemical changes, these signals are 
translated  into  the  activation  of  specific 
transcription  factors,  such  as  NF-κB  and  NF-κB-
like  transcription  factors,  that  drive  further  gene 
activation.
27
Additional  interactions  between  platelets 
include monocyte triggering receptor expressed on 
myeloid  cell  1  (TREM-1)  to  platelet-expressed 
TREM-1  ligand  which  may  promote  integrin 
expression.
28
More  recently,  SCUBE1  (signal  peptide-CUB 
(complement  C1r/C1s,  Uegf,  and  Bmp1)-EGF 
(epidermal  growth  factor)-like  domain-containing 
protein  1,  a  protein  associated  with  platelet-
endothelial interactions, was reported as a marker of 
platelet activation occurring during acute ischemic 
stroke,  being  virtually  undetectable  in  healthy
subjects.
29 SCUBE-1 belongs to a novel family of 
proteins,  is  stored  in  the  α-granules  of  inactive 
platelets,  translocated to  the platelet  surface upon 
thrombin  activation,  released  after  proteolytic 
cleavage  as  small  soluble  fragments,  and 
incorporated into thrombus. Since EGF-like repeats 
are  well  known  to  mediate  adhesive  interactions, 
the amino terminal EGF-repeats of SCUBE1 might 
function  as  a  novel  platelet-endothelial  adhesion 
molecule  and  play  a  pathogenetic  role  in 
cardiovascular biology. 
Table  1 lists  the  major  adhesion  molecules 
involved  in  endothelium,  platelet  and  leukocyte 
interactions.
Other  functionally  active  products  (and 
markers)  of  cell-cell  interactions  are  the 
transcellular metabolites of arachidonic acid. These 
can be either metabolites produced by cooperation 
between  different  cell  types,  in  which  monocytes 
provide  leukotriene  A4  for  metabolic  conversion 
into  leukotriene  C4  by  platelets
30,31 and  calcium 
ionophore-stimulated  neutrophil-platelet 
coincubations  lead  to  the  formation  of  lipoxin 
A4,
32,33 or  single  cell  products,  such  as  LTB4  in 
leukocytes  or  thromboxane  (Tx)  B2  in  platelets, 
produced in greater amount thanks to the presence 
or adhesion with a different cell.
3,5,11
Platelet-leukocyte  interaction  in  blood 
coagulation: Platelets and monocytes colocalize in 
the  area  of  vascular  injury.  Indeed,  such  an 
interaction  has  been  shown  to  occur  in  areas  of 
vessel damage, at sites of inflammation, and at sites 
of thrombosis.
34-36 Increasing evidence that platelets 
and  their  interaction  with  inflammatory  cells  are 
essentially involved in the initiation and progression 
of  atherosclerosis  have  been  provided  in  recent 
years.
37 This  close  apposition  facilitates  the 
interactions  between  the  biochemical  pathways 
present in the two cell types leading to upregulation 
of the cell procoagulant activity. Although an early 
report  described  a  platelet  factor  X  activating 
activity in a purified system in which platelets were 
incubated  with  leukocytes  in  the  presence  of 
bacterial  endotoxin  lipopolysaccharide  (LPS),
38
current  evidence  linking  platelets  and  monocytes 
with blood coagulation is related to modulation of 
TF procoagulant activity. 
TF is a 47-kD integral membrane glycoprotein 
associated with phospholipids, which, upon binding 
to factor VII and its active form VIIa, triggers blood 
coagulation  leading  to  fibrin  formation.
39 TF  is 
constitutively expressed in extravascular cells, in a 
pattern consistent with the hypothesis that TF can 
be  considered  as  a  “hemostatic envelope”, whose 
duty is to minimize blood loss when the integrity of 
the vasculature is compromised.
40 Although under 
normal conditions vascular cells do not express TF 
antigen or activity, these cells, exposed to mediators 
elaborated  during  inflammatory  reactions,  can  be 
induced  to  synthesize  and  express  TF on  their 
membranes.
41
Although it is widely accepted that, among the 
white  cells,  the  monocyte/macrophage  is  the  cell 
capable  to  synthesize  TF,  recently,  in  in  vitro
models, induction of TF expression in neutrophils 
exposed  to  P-selectin  and  fMLP
42 or  to  the 
complement component C5a
43 have been reported. 
Neutrophil TF expression is still, however, a matter 
of  discussion:  at  odd  with  the  above  mentioned 
findings, in which the presence of mRNA coding 
for TF was shown,
42 a recent report suggests that 
neutrophils  do  not  express  but  acquire  TF  from 
monocytes.
44 The  presence  of  TF  in  platelets has 
also been documented.
45 Both a surface-associated 
TF  activity
46  and  the  presence  of  TF  in  the 
supernatant of activated platelets
47 were reported. In 
addition, the presence of TF mRNA and pre-mRNA 
in  platelets  has been  demonstrated,
47,48 suggesting 
that these  cells have the necessary “repertoire” to 
synthesize and express TF. However, although the 
expression of TF on monocyte membranes, and the 
consequent  activation  of  coagulation,  has  been 
shown to be involved in thrombus formation in a 
variety  of  pathological  conditions,
41,49 a  role  for 
neutrophils and platelet TF in  vivo remains to be 
established.Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
Table 1. Major adhesion molecules in endothelium, platelet and leukocyte interactions
Back in Seventies, Niemetz and Marcus
50 first 
reported that platelets could induce TF activity in 
mononuclear  cells  and increase  it  when the  latter 
cells  were  stimulated  by  LPS.  Following  this 
pioneering  observation,  the  effect  of  platelets  in 
inducing and/or enhancing monocyte TF activity in 
washed  cell  systems  was  later  on  reported  by 
others.
51,52 In a whole blood system, Amirkhosravi 
et  al
53 reported  that  stimulated  monocyte  TF 
expression was directly proportional to the platelet 
count  and  was  reduced  by  ingestion  of  aspirin. 
Similarly, platelet up-regulation of the expression of 
TF procoagulant activity in mononuclear cells was 
significantly  impaired  by  pretreatment  with  the 
active  metabolite  of  the  antiplatelet  drug 
clopidogrel.
54 Noteworthy,  in  addition  to  TF 
induction,  platelet-monocyte  aggregates  increase 
the expression  of monocyte chemotactic protein-1 
and  interleukin  8,  proinflammatory  cytokines 
related to the progression of atherosclerosis.
55-57
The observation that TF activity correlated with 
the number of platelets, arachidonic acid amplified 
TF expression, and platelets from donors who had 
ingested  acetylsalicylic  acid  were  more  effective, 
suggested a role for a platelet-derived lipoxygenase 
pathway  metabolite.  Indeed,  platelet-derived  12-
hydroxyeicosatetraenoic  acid  (12-HETE),  the  end
product  of  the  12-lipoxygenase-mediated  pathway 
of arachidonic acid, upregulated TF expression in 
LPS-stimulated mononuclear cells.
58 In addition to 
12-HETE, PF4, another platelet-derived metabolite, 
was  later  reported  to  increase  TF  activity  in 
stimulated monocytes.
59
A  role  for  granulocytes  in  modulation  of  TF 
expression during platelet-monocyte interaction has 
also  been  suggested.  In  this  respect,  granulocytes 
were  proposed  to  be  required  for  optimal  TF 
activity in  LPS-stimulated monocytes  coincubated 
with  platelet:  the  release  of  the  granulocyte 
lysosomal  enzyme  cathepsin  G,  which  induces 
platelet activation,
60,61 would increase monocyte TF 
activity.
62
Contact between platelets and monocytes was 
required  to  elicit  monocyte  TF,  suggesting  the 
involvement of one or more adhesion molecules.
63
Among  the  different  possibilities,  P-selectin 
appeared to be the optimal candidate. A role for P-
selectin  in  the  haemostatic  process  has  been 
proposed  in  an  in  vivo system.  Accumulation  of 
leukocytes  on  activated  platelets  and  fibrin 
formation  in  a  Dacron  graft  implanted  within  an 
arterio-venous shunt in a baboon were reduced by 
Molecule Origin and expression Function Ligand
Selectins
P-selectin Stored in EC and platelet granules;expressed 
on cell surface on stimulation and released
Rolling of leukocytes on EC 
and platelets and of platelets 
on EC
PSGL-1
E-selectin Induced by cytokines on EC Rolling of leukocytes on EC PSGL-1 ESL-1
CD44
L-selectin Expressed on leukocytes Secondary leukocyte 
recruitment PSGL-1
Immunoglobulins
ICAM-1 Up-regulated by cytokines on EC and 
leukocytes
Firm adhesion and 
transmigration of leukocytes β2-integrins
ICAM-2 Constitutive on EC and platelets
Firm adhesion and 
transmigration of leukocytes; 
platelet adhesion to 
leukocytes
β2-integrins
VCAM-1 Up-regulated by cytokines on EC Firm adhesion and 
transmigration of leukocytes α4-integrins
PECAM-1 Constitutive on EC, platelets and leukocytes Transmigration PECAM-1
Integrins
β2-integrins Expressed on leukocytes;
require activation 
Firm adhesion to EC and 
platelets
ICAMs VCAM
fibrinogen
β3-integrins
Expressed on platelets (αIIbβ3 or GpIIbIIIa) 
and on neutrophils/EC (αVβ3); require 
activation
Firm cell adhesion
Fibrinogen;
extracellular 
matrix molecules
Tumor necrosis factor 
family
CD40
CD40L
Constitutive and expressed on EC, leukocyte 
and platelet surface
Activates different EC, 
leukocyte and platelet 
function
CD40L
CD40; αIIb β3 on 
plateletsMedit J Hemat Infect Dis 2010; 2(3): Open Journal System
pretreatment  of  the  baboon  with  anti-P-selectin 
monoclonal antibodies, indicating that P-selectin in 
vivo is  responsible  for  platelet-leukocyte binding 
within  the  thrombus,  and  that  these  leukocytes 
promote  fibrin  formation.
16 Indeed,  both  highly 
purified P-selectin and Chinese hamster ovary cells 
transfected with the P-selectin cDNA, but not with 
E-selectin,  induce monocyte  TF  activity  and 
mRNA.
64 Recently,  P-selectin-dependent  platelet-
monocyte  aggregates  were  reported  to  upregulate 
TF expression in a whole blood system.
57 A role for 
P-selectin  in  mediating  the  stimulatory  effect  of 
platelets  and  granulocytes  on  LPS-induced  TF 
activity in monocytes was also shown.
62 In addition, 
12-HETE,  similarly  to  what  was  observed  with 
LPS-stimulated monocytes, greatly potentiated TF 
expression by P-selectin-exposed monocytes.
65
Thus, P-selectin-expressing platelets at sites of 
vascular  injury,  responsible  for  docking  of 
monocytes,  trigger  TF  synthesis  and  the  local 
activation of blood coagulation will prevent further 
blood loss. 
The discovery of what was called “blood borne 
TF” added a new milestone in  the search for  the 
mechanisms leading to arterial thrombosis. Giesen 
et al
66 reported that the appearance of TF antigen in 
growing  thrombi  formed  on  pig  arterial  media 
perfused with native blood from healthy volunteers 
was a matter of minutes, suggesting that TF was not 
due to  de novo protein  synthesis but  was already 
present in the bloodstream. Most likely this blood-
borne  circulating  TF  is  associated  with 
microparticles. It has been known for over twenty 
years  that  most  of  the  eukaryotic  cells  release 
vescicles  either  during  apoptosis  or  upon 
stimulation and  TF-positive  microparticles  have 
been  detected  in  fresh  blood  samples  of  healthy 
individuals  and  found  increased  in  patients  with 
diseases  such  as  cancer,  endotoxemia  and 
cardiovascular disease.
67,68 An intravital microscopy 
system for real-time imaging in vivo has shown a 
mandatory role for the P-selectin/PSGL-1 receptor 
pair for TF accumulation at sites of vessel injury: 
microparticles of leukocyte origin carrying TF and 
PSGL-1  would  bind  P-selectin  exposed  on  the 
surface of activated platelets recruited at the injury 
site and thus  contribute to the propagation of  the 
growing thrombus.
69,70
Finally,  the  interaction  of  P-selectin  with 
PSGL-1 has been proposed to be responsible for the 
transfer of TF microparticles from monocytes and, 
possibly, granulocytes to platelets during thrombus 
formation.
71
As  mentioned  before,  platelets  carry  another 
adhesive  protein,  namely  CD40L,  which  is 
expressed on their membrane following activation, 
and which binds its counter-receptor CD40 which is 
located  to  monocyte  and endothelial  cell 
membrane.
25 It has been shown that this interaction, 
similarly to  the P-selectin-PSGL-1 one,  triggers a 
procoagulant  response. Indeed, CD40  engagement 
in  endothelial  cells,
72 both  with  fibroblasts 
transfected  with  CD40L  gene  and  with  CD40L-
expressing activated platelets,
73 in vascular smooth 
muscle  cells,74 in  melanoma  cells
75  and  in 
monocytes
75-77  results  in  TF  expression  in  all  the 
cells tested.
Since CD40 and CD40L have been detected in 
atheromatous  plaques,
78 it  is  conceivable  that,  in
addition  to  plaque  smooth  muscle  cells,  activated 
CD40L-expressing platelets recruited at the site of 
endothelial  damage,  would  tether  monocytes  and 
induce  TF  synthesis,  thus  increasing  the 
thrombogenicity  of  the  plaque  during  the 
inflammatory  responses  of  atherogenesis  and 
arterial injury.
Soluble  adhesive  molecules:  After  cell  surface 
expression,  some  adhesive  molecules,  namely  P-
selectin,  CD40L  and  SCUBE1  from  platelets,  L-
selectin  from  leukocytes,  or  E-selectin,  ICAM-1 
and VCAM-1 from endothelium, are found in the 
circulation,  as  the  result  of  proteolytic  cleavage. 
The  biological  activity,  either  as  activators  or 
inhibitors  of  cell  function,  of  soluble  adhesive 
molecules  detected  in  the  circulation  is  not 
completely clarified, but their increased levels have 
been reported in patients at high cardiovascular risk 
in  different  studies  (hypercholesterolemia,  type  2 
diabetes),  or  associated  with  pro-inflammatory 
status or cardiovascular disease.
79-82
Whether the measurement of soluble adhesive 
molecules is merely an epiphenomenal reflection of 
the  inflammatory  and  thrombotic  processes,  or 
whether  it  directly  contributes  to  acute  coronary 
events remains to be established.
Clinical and epidemiological evidence of cell-cell 
interactions  in  cardiovascular  disease:  Despite 
the  discovery,  already  long  ago,  of  the  role  of 
platelets  in  experimental  thrombosis  and  of  the 
remarkable  antithrombotic  effect  of  antiplatelet 
drugs in several ischemic conditions, there is still 
little direct evidence that platelets play an important 
role  in the  pathogenesis of  vascular disease. This 
“platelet paradox”
83 is based on the lack of clinical 
data  showing  a  direct  relationship  between  the 
platelet  number  (and/or  platelet  function 
parameters)  and  the  number  (and/or  severity)  of 
vascular events. Data showing reduced vascular risk Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
in  thrombocytopenic  patients  and  a  proportional 
increase  of  risk  following  transfusion  of  platelets 
are  also  lacking  to  directly support  the  role  of 
platelets in thrombosis.
On  the  other  hand,  positive  correlations 
between  the  count  of  leukocytes  (neutrophil 
polymorphonuclear  -PMN-,  in  particular)  and  the 
risk of myocardial infarction and stroke have been 
suggested  since  many  years.
21,22 Cardiovascular 
events are recognized as the most important cause 
of  mortality  and  morbidity  in  patients  with 
inflammatory  rheumatoid  arthritis.
84 Leukocytosis 
has been also associated with both acute thrombosis 
and  atherosclerosis.  However,  up  to  now  no 
treatment  reducing  leukocyte  function  resulted 
effective  in  humans  and  treatment  with 
hydroxyurea, reducing leukocyte count, has not yet 
been tested in patients at high ischemic risk.
23
The  hypothesis  that  leukocytes  and  platelets 
mutually interact and contribute to the development 
of thrombotic ischemic disease is taking more and 
more  credit.  Increased  ex  vivo functional 
responsiveness as well as in vivo PMN activation 
and  platelet-leukocyte  interaction  in  different 
clinical  manifestations  of  ischemic  heart  disease 
have been reported and an active role for these cells 
in the progression of  vascular  occlusion has been 
suggested.  Although  most  platelet-leukocyte 
aggregates  have  probably  a  short  intravascular 
survival time, so that only a small fraction of the 
formed  aggregates  are  detectable  in  the  systemic 
circulation, platelet-leukocyte conjugates have been 
observed  in  peripheral  blood  from  patients  with 
unstable  angina, stable  coronary  artery disease  or 
mechanical heart valve replacement, as well as in 
patients  with  myeloproliferative  disease.
3 The 
formation  of  platelet-leukocyte  conjugates 
following percutaneous coronary interventions was 
considered  as  a  predictive  index  of  acute  re-
occlusion.
3-5,23,24,85,86
Recent in vitro work from our group
42 indicates 
that  neutrophil  activation  by  platelet  P-selectin 
results  in  TF  expression  and  synthesis,  a 
phenomenon  inhibited  in  vitro and  ex  vivo by 
hydroxyurea  in  patients  with  myeloproliferative 
disease.
87
In  the  framework  of  a  large  epidemiological 
study  conducted  by  our  group,  platelet-leukocyte 
conjugates and their determinants were evaluated in 
citrated  whole  blood  from  349  subjects  (209 
women, 16-92 years) randomly recruited from the 
general population.
88 Platelet activation obtained by 
in vitro addition of ADP/collagen, but not leukocyte 
stimulation by the inflammatory  peptide fMLP or 
by  LTB4,  resulted  in  formation  of  platelet 
conjugates  with  PMN  or  monocytes.  In  vitro
stimulation  with  ADP/collagen  significantly 
increased  basal  platelet  conjugates  with  PMN  or 
monocytes, platelet P-selectin and leukocyte CD11b 
expression.  Platelet  count  significantly  correlated 
with  platelet-PMN,  platelet-monocyte  conjugates 
and  P-selectin  both  at  baseline  and  upon 
stimulation. In all conditions, both conjugate levels 
correlated  with  each  other,  when  adjusted  for 
gender, age and platelet count. Age correlated with 
platelet-PMN  conjugate  numbers  in  basal  and 
stimulated  conditions  and  with  basal  P-selectin. 
ADP/collagen  stimulation  resulted  in  higher  P-
selectin  and conjugates  values in women. Among 
risk  factors,  a  significant  correlation  was  found 
between  cell  conjugates  and  glucose  levels.  This 
study suggests that the presence and formation of 
platelet-leukocyte  conjugates  in  citrated  whole 
blood  from  a  large  population  reflects  primary 
platelet – but not leukocyte – activation and varies 
with gender, age, platelet count and blood glucose 
levels.
Modulation of  cell-cell  interactions:  Antiplatelet 
agents,  such  as  dipyridamole,  the  thienopyridine 
clopidogrel,  the  anti-GpIIbIIIa  abciximab,  or  the 
stable prostacyclin analogue iloprost, have all been 
tested for their ability to modify platelet-leukocyte 
interactions. The control of cell-cell interactions is a 
new  concept  in  pharmacology,  including  the 
modulation of cell signalling necessary for adhesive 
molecule  expression  and  activation.  Recently, 
heparins,  and  in  particular  low  molecular  weight 
heparins,  have  been  shown  to  interfere  with 
platelet-leukocyte (and tumor cell interactions too) 
at  the  level  of  P-selectin-PSGL-1 adhesion.
89 The 
effects  of  old  or  new  drugs  or  of  diet-derived 
polyphenols
3,10,11,90  on  cellular  functions  and 
interactions  relevant  to  inflammation  and 
cardiovascular ischemic disease is beyond the scope 
of this chapter.
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